[ad_1]
Dr. Nader Pourhbadan, CEO of CytoDyn Inc., told Proactive Investors that Washington-based biotech partnered with the Thai Red Cross AIDS Research Center (TRCARC) to conduct an HIV Infection trial.
The CEO describes the differences between CytoDyn's leronlimab and the only FDA approved product for HIV prevention, Gilead Sciences (NASDAQ: GILD) Truvada.
Source link
